Bowel perforation associated sunitinib therapy for recurred gastric gastrointestinal stromal tumor
Annals of Surgical Treatment and Research
;
: 220-225, 2014.
Artículo
en Inglés
| WPRIM
| ID: wpr-133143
ABSTRACT
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. Several recent findings that there are activating mutations in the KIT and PDGFRA (platelet-derived growth factor receptor-alpha) genes of GISTs provide the rationale for using targeted therapies such as imatinib or sunitinib. Sunitinib, an oral multitargeted receptor tyrosine kinase inhibitor that inhibits kinases such as KIT, PDGFR (platelet-derived growth factor recepter), and VEGFR (vascular endothelial growth factor receptor), was recently approved for the treatment of imatinib-refractory GIST. Sunitinib is generally well tolerated and has an acceptable toxicity profile; an adverse event such as bowel perforation is rare. We present a patient with imatinib-refractory GIST who was successfully treated using sunitinib, but developed bowel perforation. The mechanism involved in bowel perforation associated with sunitinib is unknown. However, we presume that in our patient, the dramatic reduction in disseminated peritoneal metastases and bowel invasion of recurrent GIST during sunitinib treatment might have resulted in the bowel perforation.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Fosfotransferasas
/
Proteínas Tirosina Quinasas
/
Factores de Crecimiento Endotelial
/
Tracto Gastrointestinal
/
Tumores del Estroma Gastrointestinal
/
Mesilato de Imatinib
/
Perforación Intestinal
/
Metástasis de la Neoplasia
Límite:
Humanos
Idioma:
Inglés
Revista:
Annals of Surgical Treatment and Research
Año:
2014
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS